The three PMTs, SUV39H1, SUV39H2, and G9a cooperated in catalyzing trimethylation of H3K9 on the FAS promoter, resulting in decreased Fas expression in metastatic human colon carcinoma cells. FAS was identified as a target gene of verticillin A, which is a selective inhibitor against all three PMTs. This inhibitor decreased H3K9me3 levels in the FAS promoter and restored Fas expression, and also exhibited great efficacy in overcoming colon carcinoma resistance to FasL-induced apoptosis. Use of this inhibitor helped overcome metastatic colon carcinoma resistance to 5FU in vitro and in vivo. The gene discussed is EHMT2; the disease is colon carcinoma.